Test helpful for SLN-negative, stage I to IIA and thin tumors
An expert sheds light on emerging knowledge
Impact on tumor immune microenvironment and response to immunotherapy
Complimentary case-based program Aug. 24
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
New adjuvant therapies, advances in neoadjuvant
One sequence/combo = longer survival, lower costs
Many genetic alterations were related to other malignancies
Melanoma may be more heritable than we think
Prompt treatment especially important for stage I melanoma
A clinical nurse specialist leads the appointments